Brief: Sienna Biopharmaceuticals Announces Plans To Initiate Phase 3 Psoriasis Trials In Second Half Of 2019

Sienna Biopharmaceuticals

03/12/2018 12:39

Dec 3 (Reuters) - Sienna Biopharmaceuticals Inc  SNNA.O :
    * SIENNA BIOPHARMACEUTICALS ANNOUNCES ITS TOPICAL,
NON-STEROIDAL
TRKA INHIBITOR SNA-120 (0.05%) DEMONSTRATED SIGNIFICANT IMPACT
ON PSORIASIS IN PHASE 2B STUDY AND PLANS TO INITIATE PHASE 3
PSORIASIS TRIALS IN SECOND HALF OF 2019
    * SIENNA BIOPHARMACEUTICALS INC - SNA-120 WAS WELL TOLERATED
WITH
FEW TREATMENT-RELATED ADVERSE EVENTS
    * SIENNA BIOPHARMACEUTICALS INC - SUBJECTS ACHIEVED 58%
IMPROVEMENT IN ITCH FROM BASELINE ON I-NRS VERSUS 55% WITH
VEHICLE (NOT STATISTICALLY SIGNIFICANT)
    * SIENNA BIOPHARMACEUTICALS INC - 27% OF SUBJECTS ACHIEVED
75%
REDUCTION IN PASI SCORE (PASI 75) VERSUS 13% WITH VEHICLE
    * SIENNA BIOPHARMACEUTICALS INC - 29% OF SUBJECTS ACHIEVED
TWO-GRADE IMPROVEMENT ON IGA AND 'CLEAR' OR 'ALMOST CLEAR' SKIN
VERSUS 13% WITH VEHICLE
    * SIENNA BIOPHARMACEUTICALS INC - PHASE 2 STUDY EXPECTED TO
BEGIN
SECOND HALF 2019
    * SIENNA BIOPHARMACEUTICALS INC - DID NOT MEET OUR PRIMARY
ENDPOINT ON PRURITUS

Source text for Eikon:  ID:nGNXbWHPgX 
Further company coverage:  SNNA.O 

 ((Reuters.Briefs@thomsonreuters.com;))